title: Management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I.
abstract: OBJECTIVE
  Here, the aim is to study the management of octogenarians hospitalized for heart failure in Euro Heart Failure Survey I. Heart Failure (HF) is common in older people and associated with poor outcome.
  
  
  RESULTS
  We compared clinical characteristics, treatment, and short-term outcomes in 2780 octogenarians (group A, median age 85 years) and in 7912 younger patients (group B, median age 69 years) enrolled in the Euro Heart Failure Survey I. There were 37% males in group A vs. 59% in group B (P < 0.001). Co-morbidities were more common in group A. Ejection fraction was measured only in 38% in group A vs. 65% in group B (P < 0.001) and when measured was preserved in 50 vs. 40% (P < 0.001). In-hospital and 12 weeks follow-up mortality were, respectively, 13 vs. 5% (P < 0.001) and 12 vs. 6% (P < 0.001) in groups A and B. Acute cardiac conditions and co-morbidity predicted mortality, whereas the use of angiotensin-converting enzyme inhibitor (ACE-I) and beta-blockers was associated with a better outcome. ACE-I and beta-blockers were used in 50 vs. 66% (P < 0.001) and 24 vs. 42% (P < 0.001) in groups A and B, respectively, whereas diuretics, digitalis, and nitrates were more commonly used in octogenarians.
  
  
  CONCLUSIONS
  Preserved systolic function, multiple co-morbidities, and high mortality are observed in octogenarians with HF. In these patients, cardiac function is assessed in only a minority and treatments known to improve prognosis in younger patients under-utilized. Overall, the management of octogenarians with HF does not follow international guidelines.
authors.affiliation: Department of Cardiology, Pitie Salpetriere Hospital, University Pierre et Marie Curie, 47/83 boulevard de l'Hôpital, 75013 Paris, France. michael.komajda@psl.aphp.fr
authors.forename: Michel
authors.initials: M
authors.lastname: Komajda
authors.forename: Olivier
authors.initials: O
authors.lastname: Hanon
authors.forename: Matthias
authors.initials: M
authors.lastname: Hochadel
authors.forename: Ferenc
authors.initials: F
authors.lastname: Follath
authors.forename: Karl
authors.initials: K
authors.lastname: Swedberg
authors.forename: Anselm
authors.initials: A
authors.lastname: Gitt
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D005060:Europe; D005260:Female; D006333:Heart Failure / Q000401:mortality / Q000503:physiopathology / Q000628:therapy*; D006760:Hospitalization / Q000706:statistics & numerical data*; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D013318:Stroke Volume / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002316:Cardiotonic Agents